Rexulti
| Chemical Name | brexpiprazole |
| Dosage Form | Tablet (oral; 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg) |
| Drug Class | Atypical antipsychotics |
| System | Nervous |
| Company | Otsuka Pharmaceutical |
| Approval Year | 2015 |
Indication
- Indicated as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD).
- Indicated for the treatment of schizophrenia in adults and pediatric patients ages 13 years and older.